Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PCSK9 Inhibition & Neurocognitive Impairment

Circulation; ePub 2017 Nov 16; Mefford, et al

Exposure to low proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and cumulative exposure to lower low-density lipoprotein cholesterol (LDL-C) are not associated with neurocognitive effects in African Americans, a recent study found. The study examined the association between PCSK9 loss-of-function (LOF) variants and neurocognitive impairment and decline among African American REasons for Geographic and Racial Differences in Stroke (REGARDS) participants with (n=241) and without (n=10,454) C697X or Y142X LOF variants. Researchers found:

  • The prevalence of neurocognitive impairment at any assessment was 6.3% by Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) and 15.4% by Six Item Screener (SIS) definitions.
  • Adjusted odds ratios (ORs) for neurocognitive impairment for those with vs without PCSK9 LOF variants were 1.11 using the CERAD battery and 0.89 using the SIS assessment.
  • Patterns of neurocognitive decline were similar between participants with and without PCSK9 LOF variants.

Citation:

Mefford MT, Rosenson RS, Cushman M, et al. PCSK9 variants, LDL-cholesterol, and neurocognitive impairment: The REasons for geographic and racial differences in stroke (REGARDS) study. [Published online ahead of print November 16, 2017]. Circulation. doi:10.1161/CIRCULATIONAHA.117.029785.

This Week's Must Reads

Lipid Testing After Acute Myocardial Infarction, J Am Heart Assoc; ePub 2018 Jan 25; Wang, et al

Clinical Pharmadynamics of Evolocumab, Clin Pharmacokinet; ePub 2018 Jan 20; Kasichayanula, et al

Lipoproteins & CV Outcomes in Dialysis Patients, J Clin Lipidol; ePub 2017 Dec 26; Kaysen, et al

Is Dual Lipid-Lowering Therapy Better?, Atherosclerosis; 2018 Feb; Gragnano, et al

sLOX-1 in Ischemic Stroke & Transient Ischemic Attack, J Am Heart Assoc; ePub 2018 Jan 12; Skarpengland, et al

Must Reads in Hypercholesterolemia

Lipid Testing After Acute Myocardial Infarction, J Am Heart Assoc; ePub 2018 Jan 25; Wang, et al

Clinical Pharmadynamics of Evolocumab, Clin Pharmacokinet; ePub 2018 Jan 20; Kasichayanula, et al

Lipoproteins & CV Outcomes in Dialysis Patients, J Clin Lipidol; ePub 2017 Dec 26; Kaysen, et al

Is Dual Lipid-Lowering Therapy Better?, Atherosclerosis; 2018 Feb; Gragnano, et al

sLOX-1 in Ischemic Stroke & Transient Ischemic Attack, J Am Heart Assoc; ePub 2018 Jan 12; Skarpengland, et al